Role of vasopressin antagonists in the management of acute decompensated heart failure.

Cesare Orlandi; Christopher A. Zimmer; Mihai Gheorghiade

doi:10.1007/s11897-005-0021-3

Role of vasopressin antagonists in the management of acute decompensated heart failure.

Cesare Orlandi^*, Christopher A. Zimmer, Mihai Gheorghiade

^*Corresponding author for this work

Medicine, Cardiology Division

Research output: Contribution to journal › Review article › peer-review

5 Scopus citations

Abstract

Vasopressin antagonists are a class of neurohormonal antagonists with applications in both the short-term and long-term management of patients with acute decompensated heart failure (ADHF). The pharmacologic effects of vasopressin antagonists include changes in fluid balance and hemodynamics that may improve symptoms and outcomes in patients hospitalized with ADHF. With chronic therapy, vasopressin antagonists offer the potential to improve outcomes through a variety of mechanisms, including more effective treatment of congestion, preservation or improvement of renal function, or a reduction in the use of concomitant loop diuretic therapy. Several vasopressin antagonists are currently in advanced clinical trials for the treatment of ADHF, chronic stable heart failure, and hyponatremia.

Original language	English (US)
Pages (from-to)	131-139
Number of pages	9
Journal	Current heart failure reports
Volume	2
Issue number	3
DOIs	https://doi.org/10.1007/s11897-005-0021-3
State	Published - Sep 2005

ASJC Scopus subject areas

Emergency Medicine
Cardiology and Cardiovascular Medicine
Physiology (medical)

Access to Document

10.1007/s11897-005-0021-3

Cite this

@article{49ab4a084cce4857a79a3b25edfb424f,

title = "Role of vasopressin antagonists in the management of acute decompensated heart failure.",

abstract = "Vasopressin antagonists are a class of neurohormonal antagonists with applications in both the short-term and long-term management of patients with acute decompensated heart failure (ADHF). The pharmacologic effects of vasopressin antagonists include changes in fluid balance and hemodynamics that may improve symptoms and outcomes in patients hospitalized with ADHF. With chronic therapy, vasopressin antagonists offer the potential to improve outcomes through a variety of mechanisms, including more effective treatment of congestion, preservation or improvement of renal function, or a reduction in the use of concomitant loop diuretic therapy. Several vasopressin antagonists are currently in advanced clinical trials for the treatment of ADHF, chronic stable heart failure, and hyponatremia.",

author = "Cesare Orlandi and Zimmer, {Christopher A.} and Mihai Gheorghiade",

year = "2005",

month = sep,

doi = "10.1007/s11897-005-0021-3",

language = "English (US)",

volume = "2",

pages = "131--139",

journal = "Current Heart Failure Reports",

issn = "1546-9530",

publisher = "Current Science, Inc.",

number = "3",

}

TY - JOUR

T1 - Role of vasopressin antagonists in the management of acute decompensated heart failure.

AU - Orlandi, Cesare

AU - Zimmer, Christopher A.

AU - Gheorghiade, Mihai

PY - 2005/9

Y1 - 2005/9

N2 - Vasopressin antagonists are a class of neurohormonal antagonists with applications in both the short-term and long-term management of patients with acute decompensated heart failure (ADHF). The pharmacologic effects of vasopressin antagonists include changes in fluid balance and hemodynamics that may improve symptoms and outcomes in patients hospitalized with ADHF. With chronic therapy, vasopressin antagonists offer the potential to improve outcomes through a variety of mechanisms, including more effective treatment of congestion, preservation or improvement of renal function, or a reduction in the use of concomitant loop diuretic therapy. Several vasopressin antagonists are currently in advanced clinical trials for the treatment of ADHF, chronic stable heart failure, and hyponatremia.

AB - Vasopressin antagonists are a class of neurohormonal antagonists with applications in both the short-term and long-term management of patients with acute decompensated heart failure (ADHF). The pharmacologic effects of vasopressin antagonists include changes in fluid balance and hemodynamics that may improve symptoms and outcomes in patients hospitalized with ADHF. With chronic therapy, vasopressin antagonists offer the potential to improve outcomes through a variety of mechanisms, including more effective treatment of congestion, preservation or improvement of renal function, or a reduction in the use of concomitant loop diuretic therapy. Several vasopressin antagonists are currently in advanced clinical trials for the treatment of ADHF, chronic stable heart failure, and hyponatremia.

UR - http://www.scopus.com/inward/record.url?scp=33644833004&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644833004&partnerID=8YFLogxK

U2 - 10.1007/s11897-005-0021-3

DO - 10.1007/s11897-005-0021-3

M3 - Review article

C2 - 16138949

AN - SCOPUS:33644833004

SN - 1546-9530

VL - 2

SP - 131

EP - 139

JO - Current Heart Failure Reports

JF - Current Heart Failure Reports

IS - 3

ER -

Role of vasopressin antagonists in the management of acute decompensated heart failure.

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this